ADBiotech Past Earnings Performance
Past criteria checks 0/6
ADBiotech has been growing earnings at an average annual rate of 8.8%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 2.3% per year.
Key information
8.8%
Earnings growth rate
32.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 2.3% |
| Return on equity | -254.0% |
| Net Margin | -84.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How ADBiotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 9,824 | -8,342 | 5,996 | 1,411 |
| 31 Mar 24 | 9,721 | -6,885 | 5,463 | 1,497 |
| 31 Dec 23 | 10,472 | -2,863 | 5,832 | 1,486 |
| 30 Sep 23 | 10,505 | 3,462 | 5,534 | 1,513 |
| 30 Jun 23 | 9,608 | 4,145 | 4,953 | 1,469 |
| 31 Mar 23 | 10,648 | 3,221 | 6,703 | 1,264 |
| 31 Dec 22 | 10,632 | 2,696 | 6,720 | 1,111 |
| 30 Sep 22 | 12,397 | -2,005 | 7,403 | 708 |
| 30 Jun 22 | 12,321 | -2,542 | 7,665 | 633 |
| 31 Mar 22 | 12,566 | -2,917 | 6,432 | 755 |
| 31 Dec 21 | 11,840 | -2,664 | 5,752 | 550 |
| 31 Dec 20 | 9,815 | -7,345 | 4,450 | 788 |
Quality Earnings: A179530 is currently unprofitable.
Growing Profit Margin: A179530 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A179530 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare A179530's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A179530 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A179530 has a negative Return on Equity (-253.98%), as it is currently unprofitable.